J&J to Invest $1B in New Pennsylvania Plant Boosting US Manufacturing

• The Pennsylvania facility will produce cell therapies for cancer, immune disorders, and neurological diseases, expanding capacity beyond J&J's currently approved cell therapy Carvykti for multiple myeloma
• J&J's investment follows the U.S. government's October imposition of tariffs on branded drugs, with exemptions for producers already building U.S. plants
• The company already operates 10 facilities in Pennsylvania with an estimated $10 billion annual economic impact and announced a separate North Carolina plant as part of its multi-billion dollar U.S. expansion

Johnson & Johnson Announces $1B Pennsylvania Cell Therapy Facility

Johnson & Johnson announced Wednesday it will invest over $1 billion to construct a new cell therapy manufacturing facility in Montgomery County, Pennsylvania, as part of its strategic response to President Trump's tariff policies and push for domestic manufacturing.

Key Investment Details:

• The new plant will create more than 4,000 construction jobs and 500 permanent biomanufacturing positions
• Investment is part of J&J's broader commitment announced in March to expand U.S. manufacturing through early 2029
• The facility will focus on producing medicines for cancer, immune disorders, and neurological diseases
• J&J currently operates one approved cell therapy, Carvykti, for treating multiple myeloma

Market Context:

The announcement comes amid heightened pressure from the Trump administration's tariff threats on the pharmaceutical sector. The U.S. government imposed tariffs on branded drugs in October but exempted producers already breaking ground on domestic facilities. This has prompted major pharmaceutical companies including Eli Lilly and Novo Nordisk to commit billions toward expanding their U.S. manufacturing footprint.

Company Footprint:

J&J already maintains 10 facilities in Pennsylvania with an estimated $10 billion annual economic impact. The company also announced plans for a separate plant in Wilson, North Carolina, and previously committed to a Holly Springs, North Carolina facility through a 10-year agreement with Fujifilm Biotechnologies.

The investment underscores the pharmaceutical industry's strategic shift toward domestic production in response to evolving trade policies and represents a significant expansion of J&J's biomanufacturing capabilities in the United States. No operational start date was disclosed for the new Pennsylvania facility.